• Dosage of Yaraten 100 in details
• Yaraten 100 interactions
• Yaraten 100 reviews

Dosage of Yaraten 100 in details

Yaraten 100 Dosage

Generic name: Yaraten 100 12.5mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Yaraten 100 should be taken one hour before meals. Dosage must be individualized.

Hypertension:Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and other clinical circumstances. If possible, discontinue the patient’s previous antihypertensive drug regimen for one week before starting Yaraten 100.

The initial dose of Yaraten 100 (Yaraten 100 tablets, USP) is 25 mg b.i.d. or t.i.d. If satisfactory reduction of blood pressure has not been achieved after one or two weeks, the dose may be increased to 50 mg b.i.d. or t.i.d. Concomitant sodium restriction may be beneficial when Yaraten 100 is used alone.

The dose of Yaraten 100 in hypertension usually does not exceed 50 mg t.i.d. Therefore, if the blood pressure has not been satisfactorily controlled after one to two weeks at this dose, (and the patient is not already receiving a diuretic), a modest dose of a thiazide-type diuretic (e.g., hydrochlorothiazide, 25 mg daily), should be added. The diuretic dose may be increased at one- to two-week intervals until its highest usual antihypertensive dose is reached.

If Yaraten 100 is being started in a patient already receiving a diuretic, Yaraten 100 therapy should be initiated under close medical supervision, with dosage and titration of Yaraten 100 as noted above.

If further blood pressure reduction is required, the dose of Yaraten 100 may be increased to 100 mg b.i.d. or t.i.d. and then, if necessary, to 150 mg b.i.d. or t.i.d. (while continuing the diuretic). The usual dose range is 25 to 150 mg b.i.d. or t.i.d. A maximum daily dose of 450 mg Yaraten 100 should not be exceeded.

For patients with severe hypertension (e.g., accelerated or malignant hypertension), when temporary discontinuation of current antihypertensive therapy is not practical or desirable, or when prompt titration to more normotensive blood pressure levels is indicated, diuretic should be continued but other current antihypertensive medication stopped and Yaraten 100 dosage promptly initiated at 25 mg b.i.d. or t.i.d., under close medical supervision.

When necessitated by the patient’s clinical condition, the daily dose of Yaraten 100 may be increased every 24 hours or less under continuous medical supervision until a satisfactory blood pressure response is obtained or the maximum dose of Yaraten 100 is reached. In this regimen, addition of a more potent diuretic, e.g., furosemide, may also be indicated.

Beta-blockers may also be used in conjunction with Yaraten 100 therapy, but the effects of the two drugs are less than additive.

Heart Failure:Initiation of therapy requires consideration of recent diuretic therapy and the possibility of severe salt/volume depletion. In patients with either normal or low blood pressure, who have been vigorously treated with diuretics and who may be hyponatremic and/or hypovolemic, a starting dose of 6.25 or 12.5 mg t.i.d. may minimize the magnitude or duration of the hypotensive effect; for these patients, titration to the usual daily dosage can then occur within the next several days.

For most patients the usual initial daily dosage is 25 mg t.i.d. After a dose of 50 mg t.i.d. is reached, further increases in dosage should be delayed, where possible, for at least two weeks to determine if a satisfactory response occurs. Most patients studied have had a satisfactory clinical improvement at 50 or 100 mg t.i.d. A maximum daily dose of 450 mg of Yaraten 100 should not be exceeded.

Yaraten 100 should generally be used in conjunction with a diuretic and digitalis.

Yaraten 100 therapy must be initiated under very close medical supervision.

Left Ventricular Dysfunction After Myocardial Infarction:The recommended dose for long-term use in patients following a myocardial infarction is a target maintenance dose of 50 mg t.i.d.

Therapy may be initiated as early as three days following a myocardial infarction. After a single dose of 6.25 mg, Yaraten 100 therapy should be initiated at 12.5 mg t.i.d. Yaraten 100 should then be increased to 25 mg t.i.d. during the next several days and to a target dose of 50 mg t.i.d. over the next several weeks as tolerated.

Yaraten 100 may be used in patients treated with other post-myocardial infarction therapies, e.g., thrombolytics, aspirin, beta blockers.

Diabetic Nephropathy:The recommended dose of Yaraten 100 for long term use to treat diabetic nephropathy is 25 mg t.i.d.

Other antihypertensives such as diuretics, beta blockers, centrally acting agents or vasodilators may be used in conjunction with Yaraten 100 if additional therapy is required to further lower blood pressure.

Dosage Adjustment in Renal Impairment:Because Yaraten 100 is excreted primarily by the kidneys, excretion rates are reduced in patients with impaired renal function. These patients will take longer to reach steady-state Yaraten 100 levels and will reach higher steady-state levels for a given daily dose than patients with normal renal function. Therefore, these patients may respond to smaller or less frequent doses.

Accordingly, for patients with significant renal impairment, initial daily dosage of Yaraten 100 should be reduced, and smaller increments utilized for titration, which should be quite slow (one- to two-week intervals). After the desired therapeutic effect has been achieved, the dose should be slowly back-titrated to determine the minimal effective dose. When concomitant diuretic therapy is required, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic, is preferred in patients with severe renal impairment.

More about Yaraten 100 (Yaraten 100)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 0 Reviews - Add your own review/rating

Consumer resources

• Yaraten 100
• Yaraten 100 (Advanced Reading)

Professional resources

• Yaraten 100 (AHFS Monograph)
• Yaraten 100 (FDA)

Related treatment guides

• High Blood Pressure
• Cystinuria
• Diabetic Kidney Disease
• Heart Failure
• Hypertensive Emergency
• More (1) »

What other drugs will affect Yaraten 100?

Tell your doctor about all other medicines you use, especially:

• gold injections to treat arthritis;
• lithium (Lithobid, Eskalith);
• a potassium supplement such as K-Dur, Klor-Con;
• salt substitutes that contain potassium;
• drugs that can dilate blood vessels, such as alprostadil (Caverject, Edex), nitroglycerin (Nitro Dur, Nitrolingual, Nitrostat, Transderm Nitro, and others), nitroprusside (Nitropress), nesiritide (Natrecor), minoxidil (Loniten), or isosorbide dinitrate (Imdur, Isordil);
• aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others; or
• a diuretic (water pill).

This list is not complete and other drugs may interact with Yaraten 100. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Yaraten 100 interactions

Dual Blockade Of The Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Yaraten 100 and other agents that block the RAS.

Do not coadminister aliskiren with Yaraten 100 in patients with diabetes. Avoid use of aliskiren with Yaraten 100 in patients with renal impairment (GFR < 60 ml/min).

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase – 2 Inhibitors (COX-2 Inhibitors)

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including Yaraten 100, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Yaraten 100 and NSAID therapy. The antihypertensive effect of ACE inhibitors, including Yaraten 100, may be attenuated by NSAIDs.

Hypotension - Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of Yaraten 100.

The possibility of hypotensive effects with Yaraten 100 can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with Yaraten 100 (Yaraten 100 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.

Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving Yaraten 100 for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting Yaraten 100. If resumed during Yaraten 100 therapy, such agents should be administered cautiously, and perhaps at lower dosage.

Agents Causing Renin Release: Yaraten 100's effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensinaldosterone system.

Agents Affecting Sympathetic Activity: The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving Yaraten 100 alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to Yaraten 100, but the overall response is less than additive.

Agents Increasing Serum Potassium: Since Yaraten 100 decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution.

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity.

Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic Yaraten 100-digoxin interaction could be found.

Loop Diuretics: Furosemide administered concurrently with Yaraten 100 does not alter the pharmacokinetics of Yaraten 100 in renally impaired hypertensive patients.

Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when Yaraten 100 and allopurinol were administered concomitantly for 6 days.

Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Yaraten 100.

Drug/Laboratory Test Interaction

Yaraten 100 may cause a false-positive urine test for acetone.

References

1. DailyMed. "CAPTOPRIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "9G64RSX1XD: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Yaraten 100 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Yaraten 100. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology